1-(9-MERCAPTONONYL)-3,6,9-TRIOXAUNDECAN-11-OL, 97.0%, 250mg

E-Plan phase EPLPHi 10x/0.25 infinity corrected IOS objective. Working distance 5.95 mm

1,1,1,3,3,3-Hexafluoro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol, 98%, 2.5g

1-cyclopentyl-1,4-diazepane bis(4-methylbenzenesulfonate), 95.0%, 1g

3-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine, 97%, 250mg

(3R,4R)-tert-Butyl 3-fluoro-4-hydroxypyrrolidine-1-carboxylate, 95.0%, 1g

3,3-DIFLUORO-4-METHYLPIPERIDINE HCL, 95.0%, 250mg

Methyl 5-amino-4-cyano-1H-pyrazole-1-carboxylate, 95.0%, 500mg

4,9-DibroMo-2,7-bis(2-ethylhexyl)benzo[lMn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone, 98%, 1g

4-CHLOROISOQUINOLIN-5-AMINE, 95.0%, 1g

Wide mouth bottle type 2106, brown, 1000 ml, 6 Piece(s)

5-Chlorothiophene-2-carboxylic Acid>95.0%(GC)(T)25g

2-(2-(Tert-butyl)phenoxy)ethan-1-amine, 98%, 50mg